JP2023510491A5 - - Google Patents
Info
- Publication number
- JP2023510491A5 JP2023510491A5 JP2022534852A JP2022534852A JP2023510491A5 JP 2023510491 A5 JP2023510491 A5 JP 2023510491A5 JP 2022534852 A JP2022534852 A JP 2022534852A JP 2022534852 A JP2022534852 A JP 2022534852A JP 2023510491 A5 JP2023510491 A5 JP 2023510491A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- oligonucleotide according
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020002715 | 2020-01-10 | ||
| JP2020002715 | 2020-01-10 | ||
| PCT/JP2021/000543 WO2021141121A1 (en) | 2020-01-10 | 2021-01-08 | Novel tlr9 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510491A JP2023510491A (ja) | 2023-03-14 |
| JP2023510491A5 true JP2023510491A5 (enExample) | 2023-06-19 |
| JP7750525B2 JP7750525B2 (ja) | 2025-10-07 |
Family
ID=76787976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534852A Active JP7750525B2 (ja) | 2020-01-10 | 2021-01-08 | 新規なｔｌｒ９アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12686870B2 (enExample) |
| EP (1) | EP4087931B1 (enExample) |
| JP (1) | JP7750525B2 (enExample) |
| KR (1) | KR20220125218A (enExample) |
| CN (1) | CN114981436A (enExample) |
| AU (1) | AU2021206355B2 (enExample) |
| BR (1) | BR112022007935A2 (enExample) |
| CA (1) | CA3161956A1 (enExample) |
| IL (1) | IL294621A (enExample) |
| MX (1) | MX2022005633A (enExample) |
| WO (1) | WO2021141121A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022249092A1 (en) * | 2021-04-01 | 2023-10-12 | Trisalus Life Sciences, Inc. | Cancer therapy using toll-like receptor agonists |
| CN117568339A (zh) * | 2023-01-19 | 2024-02-20 | 华普生物技术(河北)股份有限公司 | CpG寡核苷酸及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| RU2400538C2 (ru) | 2005-03-05 | 2010-09-27 | Сиджен, Инк. | Олигонуклеотид с двойственной специфичностью и способы, в которых он используется |
| WO2006095941A1 (en) | 2005-03-05 | 2006-09-14 | Seegene, Inc. | Processes using dual specificity oligonucleotide and dual specificity oligonucleotide |
| JP5011520B2 (ja) | 2005-08-12 | 2012-08-29 | 国立大学法人 長崎大学 | 新規ヒト形質細胞様樹状細胞株 |
| JP2010536787A (ja) | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| US20110136897A1 (en) | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
| KR101856462B1 (ko) | 2009-03-25 | 2018-05-10 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물 |
| JP6106280B2 (ja) | 2012-11-29 | 2017-03-29 | Ｓｂｉバイオテック株式会社 | 阻害性オリゴヌクレオチド及びその使用 |
| CN105518153A (zh) | 2013-06-20 | 2016-04-20 | 因姆内克斯普雷斯私人有限公司 | 生物标志物鉴定 |
| KR102779525B1 (ko) | 2015-05-29 | 2025-03-12 | 다이나박스 테크놀로지 코퍼레이션 | 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 |
| EP3302501B1 (en) * | 2015-05-29 | 2021-09-22 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| CA3020873A1 (en) | 2016-04-15 | 2017-10-19 | Dynavax Technologies Corporation | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
| MX2019005502A (es) | 2016-11-09 | 2020-10-01 | Univ Texas | Metodos y composiciones para inmunomodulacion adaptativa. |
-
2021
- 2021-01-08 US US17/787,687 patent/US12686870B2/en active Active
- 2021-01-08 IL IL294621A patent/IL294621A/en unknown
- 2021-01-08 KR KR1020227017755A patent/KR20220125218A/ko active Pending
- 2021-01-08 WO PCT/JP2021/000543 patent/WO2021141121A1/en not_active Ceased
- 2021-01-08 CN CN202180010073.7A patent/CN114981436A/zh active Pending
- 2021-01-08 EP EP21738230.8A patent/EP4087931B1/en active Active
- 2021-01-08 MX MX2022005633A patent/MX2022005633A/es unknown
- 2021-01-08 BR BR112022007935A patent/BR112022007935A2/pt unknown
- 2021-01-08 JP JP2022534852A patent/JP7750525B2/ja active Active
- 2021-01-08 CA CA3161956A patent/CA3161956A1/en active Pending
- 2021-01-08 AU AU2021206355A patent/AU2021206355B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109843902B (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
| JP2023543803A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2008523094A5 (enExample) | ||
| JP2021500064A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| JP2018527013A5 (enExample) | ||
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| JP2015532097A5 (enExample) | ||
| US20120190732A1 (en) | Multifunctional Aptamer-Nucleic Acid Nanostructures for Tumor-Targeted Killing | |
| JP2006502694A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| PE20220574A1 (es) | Oligonucleotidos gapmer modificados y metodos de uso | |
| CN107693797A (zh) | 肽寡核苷酸缀合物 | |
| US11384357B2 (en) | Aptamers for personal care applications | |
| RU2006126643A (ru) | Олигомерные соединения для модуляции bcl-2 | |
| JP2006500958A5 (enExample) | ||
| IL265359B2 (en) | Modified oligonucleotides and pharmaceutical preparations containing them | |
| JP2018530530A5 (enExample) | ||
| US20250223592A1 (en) | Compositions and methods for circular rna affinity purification | |
| Lee et al. | Antisense peptide nucleic acids as a potential anti-infective agent | |
| Stephens | The emerging potential of Aptamers as therapeutic agents in infection and inflammation | |
| CA2808233A1 (en) | Aptamers to 4-1bb and their use in treating diseases and disorders | |
| JP2021518159A5 (enExample) | ||
| JP2022536945A5 (enExample) |